drugset / Trial / NCT05244993
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Phase 2
Unknown
42 enrolled
Liaoning Cancer Hospital & Institute
Anshan Tumor Hospital · collabChaoyang Central Hospital · collabFukuang General Hospital of Liaoning health industry group · collabHuludao central hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial used a multicentre, single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel. Patients included in this trial were advanced breast cancer with hormone receptor negative and Her2 negative. The primary endpoint is ORR, and the secondary endpoint is DCR, PFS, OS and safety.
Timeline
- Start
- 2022-07
- Primary completion
- 2024-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |